Silo Pharma Inc's Comment on Competition and Industry Peers
The company operates in the rare disease therapeutics industry, which is highly competitive and includes major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and medical research organizations. Competitors often possess established markets and greater financial, technical, and human resources, along with more experience in developing, manufacturing, and marketing therapies. The company relies on licensors UMB and Columbia, which accounted for 100% of its vendor license agreements for 2024 and 2025.
June 26, 2024
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and AnxietySarasota-based biopharmaceutical company, Silo Pharma, has recently announced a partnership with AmplifyBio to advance the development of their novel intranasal therapeutic, SPC-15, specifically designed for the treatment of post-traumatic stress disorder (PTSD) and anxiety. The collaboration aims to complete a Good Laboratory Practice (GLP) study of SPC-15, further evaluating its efficacy and safety profile.SPC-15 has shown promising potential as a treatment for PTSD and anxiety, offering a novel drug delivery system through intranasal administration. By targeting these conditions, Silo Pharma aims to address a significant unmet medi...
April 23, 2024
Silo Pharma s Intranasal PTSD Treatment Shows Promising Results: Revolutionizing Therapy DeliveryIn recent years, the field of mental health has witnessed revolutionary advancements in the treatment of Post-Traumatic Stress Disorder (PTSD). Silo Pharma, a prominent biopharmaceutical company, has recently announced positive results for their groundbreaking intranasal PTSD treatment, SPC-15, which has shown rapid and effective drug exposure for therapy. This new approach holds tremendous potential for transforming how PTSD is managed, offering hope for millions of individuals suffering from this debilitating condition.PTSD, a mental health disorder triggered by traumatic events, affects a significant portion o...
Sources:
Silo Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Silo Pharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
